Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Ann Daly.

Newcastle AuthorsTitleYearFull text
Dr Rebecca Darlay
Professor Heather Cordell
Professor Quentin Anstee
Professor Ann Daly
A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation2022
Dr Wei-yu Lin
Dr Sarah Fordham
Dr Nicola Sunter
Dr Claire Elstob
Dr Yaobo Xu
et al.
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (Nature Communications, (2021), 12, 1, (6233), 10.1038/s41467-021-26551-x)2022
Dr Rebecca Darlay
Professor Heather Cordell
Professor Ann Daly
Professor Chris Day
Dr Steven Masson
et al.
Corrigendum to: ‘A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers’ [J Hepatol 2022 (76) 275–282] (Journal of Hepatology (2022) 76(2) (275–282), (S0168827821021115), (10.1016/j.jhep.2021.10.005))2022
Professor Ann Daly
Epigenetics in drug disposition & drug therapy: symposium report of the 24th North American meeting of the International Society for the Study of Xenobiotics (ISSX)2022
Dr Katherine Johnson
Dr Peter Leary
Dr Olivier Govaere
Dr Matthew Barter
Sarah Charlton
et al.
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance2022
Dr Olivier Govaere
Dr Rebecca Darlay
Dr Julien Peltier
Dr Jeremy Palmer
Dr Massimo Younes
et al.
Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease2022
Dr Olivier Govaere
Professor Ann Daly
Professor Quentin Anstee
Metabolic signatures across the full spectrum of nonalcoholic fatty liver disease2022
Professor Ann Daly
Pharmacogenetics of the cytochromes P450: Selected pharmacological and toxicological aspects2022
Professor Ann Daly
Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury2021
Nardeen Eldafashi
Dr Rebecca Darlay
Dr Ruchi Shukla
Misti McCain
Robyn Watson
et al.
A pdcd1 role in the genetic predisposition to nafld-hcc?2021
Professor Ann Daly
Genetic risk factors in drug-induced liver injury due to isoniazid-containing anti-tuberculosis drug regimens2021
Dr Rebecca Darlay
Dr Steven Masson
Professor Chris Day
Professor Ann Daly
Professor Heather Cordell
et al.
Genome-wide association study and meta-analysis on alcohol-related liver cirrhosis identifies novel genetic risk factors2021
Dr Wei-Yu Lin
Dr Sarah Fordham
Dr Nicola Sunter
Dr Claire Elstob
Dr Yaobo Xu
et al.
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia2021
Dr Olivier Govaere
Dr Dina Tiniakos
Professor Pierre Bedossa
Dr Simon Cockell
Dr Massimo Younes
et al.
NASH limits anti-tumor surveillance in immunotherapy-treated HCC2021
Dr Steven Masson
Professor Ann Daly
Professor Heather Cordell
Professor Chris Day
Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers2021
Professor Ann Daly
Dr Olivier Govaere
Professor Quentin Anstee
Peptide-Based Urinary Monitoring of Fibrotic Non-Alcoholic Steatohepatitis by Mass Barcoded Activity-Based Sensors2021
Professor Ann Daly
Pharmacogenomics spotlight commentary: From the United Kingdom to global populations2021
Professor Quentin Anstee
Priyadarshini Basu
Dr Pallav Bhatnagar
Professor Ann Daly
rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis2021
Dr Olivier Govaere
Dr Simon Cockell
Professor Ann Daly
Professor Quentin Anstee
Transcriptomics Identify Thrombospondin-2 as a Biomarker for Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis2021
Professor Quentin Anstee
Dr Rebecca Darlay
Dr Simon Cockell
Dr Olivier Govaere
Dr Dina Tiniakos
et al.
Genome-Wide Association Study of Non-Alcoholic Fatty Liver and Steatohepatitis in a Histologically-Characterised Cohort2020
Professor Ann Daly
HLA associations with infliximab-induced liver injury2020
Mohammad Alshabeeb
Professor Ann Daly
Investigation of Oxidative Stress-Related Candidate Genes as Risk Factors for Drug-Induced Liver Injury due to Co-Amoxiclav2020
Professor Ann Daly
Polygenic architecture informs potential vulnerability to drug-induced liver injury2020
Dr Olivier Govaere
Dr Simon Cockell
Dr Dina Tiniakos
Dr Rachel Queen
Dr Massimo Younes
et al.
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis2020
Professor Ann Daly
A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury2019
Dr Tom Chamberlain
Dr Sally Coulthard
Mohammad Alshabeeb
Professor Ann Daly
Drug‐Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles2019
Wi Phatvej
Dr Harish Datta
Dr Simon Wilkinson
Dr Elaine Mutch
Professor Ann Daly
et al.
Endocytosis and lack of cytotoxicity of alkyl–capped silicon quantum dots prepared from porous silicon2019
Professor Ann Daly
Next-Generation Sequencing of PTGS Genes Reveals an Increased Frequency of Non-synonymous Variants among Patients with NSAID-Induced Liver Injury2019
Professor Ann Daly
Shared Genetic Risk Factors Across Carbamazepine‐Induced Hypersensitivity Reactions2019
Dr Steven Masson
Professor Ann Daly
Professor Heather Cordell
Professor Chris Day
Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis2018
Sal Bakar
Dr Peter Avery
Dr Colin Brown
Professor Ann Daly
Professor Farhad Kamali
et al.
Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case–Control Study2018
Professor Ann Daly
HLA-A∗33:03-Restricted Activation of Ticlopidine-Specific T-Cells from Human Donors2018
Professor Ann Daly
Human leukocyte antigen (HLA) and other genetic risk factors in drug-induced liver injury (DILI)2018
Professor Ann Daly
Paracetamol metabolism, hepatotoxicity, biomarkers and therapeutic interventions: A perspective2018
Professor Ann Daly
Pharmacogenetics of Adverse Drug Reactions2018
Professor Ann Daly
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations2018
Professor Ann Daly
Are Polymorphisms in Genes Relevant to Drug Disposition Predictors of Susceptibility to Drug-Induced Liver Injury2017
Dr Sally Coulthard
Professor Chris Day
Professor Ann Daly
Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study2017
Professor Ann Daly
Defining drug response for stratified medicine2017
Professor Ann Daly
Drug-Induced cholestasis: Mechanisms and importance2017
Professor Ann Daly
Drug-Induced Liver Disease2017
Professor Ann Daly
Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor2017
Professor Ann Daly
Pharmacogenetics: A general review on progress to date2017
Dr Lucy Walker
Professor Ann Daly
Dr Luca Miele
Professor Quentin Anstee
Professor Helen Reeves
et al.
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease2017
Professor Quentin Anstee
Dr Yang-Lin Liu
Dr Rebecca Darlay
Professor Heather Cordell
Professor Ann Daly
et al.
Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans2017
Professor Ann Daly
Professor Farhad Kamali
A multi-factorial analysis of response to warfarin in a UK prospective cohort2016
Dr Sally Coulthard
Professor Ann Daly
HLA-DRB1*16:01-DQB1*05:02 is a novel genetic risk factor for flupirtine-induced liver injury2016
Dr Sally Coulthard
Professor Ann Daly
Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting2016
Professor Ann Daly
The Effect of the CYP1A1*2A Allele on Colorectal Cancer Susceptibility in a British Population2016
Professor Ann Daly
Professor Chris Day
Variants in the LGALS9 Gene Are Associated With Development of Liver Disease in Heavy Consumers of Alcohol2016
Dr Sarah Steven
Dr Kieren Hollingsworth
Dr Benjamin Aribisala
Dr Ahmad Al-Mrabeh
Professor Ann Daly
et al.
Weight Loss Decreases Excess Pancreatic Triacylglycerol Specifically in Type 2 Diabetes2016
Professor Chris Day
Dr Steven Masson
Professor Ann Daly
Professor Heather Cordell
Brief Report: Genetics of Alcoholic Cirrhosis-GenomALC Multinational Study2015
Professor Ann Daly
Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury2015
Professor Ann Daly
Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands2015
Professor Quentin Anstee
Professor Ann Daly
Professor Chris Day
Genetics of Alcoholic Liver Disease2015
Dr Peter Donaldson
Professor Ann Daly
Dr Luca Ermini
Professor Debra Bevitt
Genetics of Complex Disease2015
Professor Ann Daly
Genome-wide investigation identifies common SNPs on Chr9p22.2 as risk factors for liver injury due to sulfa-methoxazole/trimethoprim2015
Professor Ann Daly
HLA-A*33:01 is strongly associated with drug-induced liver injury (DILI) due to terbinafine and several other unrelated compounds2015
Dr Jeremy Palmer
Dr Yang-Lin Liu
Professor Chris Day
Professor Ann Daly
Professor Quentin Anstee
et al.
Mechanistic Study of TM6SF2 in NAFLD pathogenesis: Stably transfected Huh7 cells over-expressing the TM6SF2 E167K variant exhibit greater levels of oxidative stress2015
Professor Ann Daly
Minocycline hepatotoxicity: Clinical characterization and identification of HLA- B*35:02 as a risk factor2015
Professor Farhad Kamali
Professor Ann Daly
Oral anticoagulation: a critique of recent advances and controversies2015
Professor Ann Daly
Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: Review of current knowledge and comparison with selected European populations2015
Professor Ann Daly
Professor Chris Day
PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease2015
Professor Ann Daly
Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases2015
Professor Ann Daly
Promiscuous T-cell responses to drugs and drug-haptens2015
Professor Farhad Kamali
Professor Ann Daly
Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants2015
Dr Harsh Sheth
Dr Michael Jackson
Dr John Tyson
Professor Ann Daly
Professor Sir John Burn
et al.
Relevance of genetic factors to warfarin dosing in India2015
Rodolphe Anty
Professor Chris Day
Professor Ann Daly
Anh Tran
Professor Quentin Anstee
et al.
The FNDC5 rs3480 is protective on the steatosis and fibrosis in patients with NAFLD2015
Professor Ann Daly
Professor Chris Day
Dr Yang-Lin Liu
Professor Quentin Anstee
TM6SF2 as a Genetic Risk Factor for Fibrosis2015
Dr Yang-Lin Liu
Professor Ann Daly
Professor Chris Day
Professor Quentin Anstee
TM6SF2: Catch-22 in the Fight Against Nonalcoholic Fatty Liver Disease and Cardiovascular Disease?2015
Ching Ng
Dr Abul Hasnat
Professor Chris Day
Professor Ann Daly
N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group2014
Dr Yang-Lin Liu
Dr Gillian Patman
Julian Leathart
Professor Alastair Burt
Professor Chris Day
et al.
Carriage of the PNPLA3 rs738409 C>G Polymorphism Confers an Increased Risk of Non-Alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma2014
Julian Leathart
Professor Ann Daly
Professor Chris Day
Professor Quentin Anstee
Gene Polymorphisms of Cellular Senescence Marker P21 and Disease Progression in Non-Alcohol-Related Fatty Liver Disease2014
Professor Ann Daly
Genetic Basis of Drug-Induced Liver Injury: Present and Future2014
Professor Ann Daly
Human Leukocyte Antigen (HLA) Pharmacogenomic Tests: Potential and Pitfalls2014
Professor Ann Daly
Is There a Need to Teach Pharmacogenetics?2014
Professor Ann Daly
Opportunities and limitations: the value of pharmacogenetics in clinical practice2014
Professor Ann Daly
Professor Farhad Kamali
Patients Benefit From Genetics-Guided Coumarin Anticoagulant Therapy2014
Professor Ann Daly
Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon2014
Professor Ann Daly
Pharmacogenomics of Warfarin2014
Dr Harsh Sheth
Dr Matthew Jackson
Dr John Tyson
Professor Ann Daly
Dr Jonathan O'Halloran
et al.
Point of care testing for improving risk- benefit ratio of aspirin and warfarin2014
Dr Yang-Lin Liu
Professor Helen Reeves
Professor Alastair Burt
Dr Dina Tiniakos
Dr Stuart McPherson
et al.
TM6SF2 rs58542926 Influences Hepatic Fibrosis Progression in Patients with Non-Alcoholic Fatty Liver Disease2014
Professor Quentin Anstee
Dr Rebecca Darlay
Julian Leathart
Yilei Liu
Professor Alastair Burt
et al.
A candidate-gene approach to validation of genetic modifier associations using a large cohort with histologically characterised non-alcoholic fatty liver disease2013
Dr Patrick Kesteven
Professor Ann Daly
Dr Peter Avery
Professor Farhad Kamali
A Randomized Trial Comparing Genotype-Guided Dosing of Warfarin to Standard Dosing: The EU Pharmacogenetics of Anticoagulant Therapy (EU-PACT) Warfarin Study2013
Dr Patrick Kesteven
Julian Leathart
Professor Ann Daly
Professor Farhad Kamali
A Randomized Trial of Genotype-Guided Dosing of Warfarin2013
Professor Gareth Veal
Julie Errington
Sophie Rowbotham
Nicola Illingworth
Dr Ghada Malik
et al.
Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma2013
Dr Yang-Lin LIU
Dr Gillian Patman
Julian Leathart
Professor Alastair Burt
Professor Chris Day
et al.
Carriage of PNPLA3 I148M is Associated with an Increased Risk of Non-Alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma2013
Dr Ahmed Elsharkawy
Dr Ulrich Schwab
Dr Brendan McCarron
Professor Alastair Burt
Professor Ann Daly
et al.
Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser2013
Professor Ann Daly
Professor Chris Day
Genetic Polymorphisms of Galectin-9 (Gal-9) Associated with Risk of Developing Alcoholic Liver Disease (ALD) in Humans2013
Professor Ann Daly
Human Leukocyte Antigen (HLA)-B(star)57:01-Restricted Activation of Drug-Specific T Cells Provides the Immunological Basis for Flucloxacillin-Induced Liver Injury2013
Professor Ann Daly
Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population2013
Professor Quentin Anstee
Dr Yang-Lin Liu
Professor Heather Cordell
Dr Rebecca Darlay
Professor Chris Day
et al.
Mapping Expression Quantitative Traits Loci (EQTL) for PNPLA3 Gene Identifies Additional SNPs Associated with Non-Alcoholic Fatty Liver Disease (NAFLD) Independent of rs7384092013
Professor Ann Daly
Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms2013
Professor Ann Daly
Pharmacogenomics of adverse drug reactions2013
Professor Ann Daly
Relevance of CYP2E1 to non-alcoholic fatty liver disease2013
Professor Ann Daly
Professor Farhad Kamali
Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs2012
Professor Ann Daly
CYP2D6 update: revised nomenclature for CYP2D7/2D6 hybrid genes2012
Professor Ann Daly
Professor Chris Day
Genetic association studies in drug-induced liver injury2012
Professor Ann Daly
Genetic polymorphisms affecting drug metabolism: recent advances and clinical aspects2012
Professor Quentin Anstee
Dr Rebecca Darlay
Julian Leathart
Professor Helen Reeves
Professor Alastair Burt
et al.
Genome-Wide Association Analysis Confirms Importance of PNPLA3 and Identifies Novel Variants Associated With Histologically Progressive Steatohepatitis in NAFLD2012
Professor Ann Daly
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs2012
Professor Ann Daly
Professor Gareth Veal
Dr David Jamieson
Dr Sally Coulthard
Pharmacogenomics research at Newcastle University2012
Ahmad Alserri
Professor Quentin Anstee
Julian Leathart
Julia Patch
Professor Chris Day
et al.
The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies2012
Dr Ellen Hatch
Dr Iain Matthews
Professor Ann Daly
Professor Farhad Kamali
The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors2012
Professor Ann Daly
Using genome-wide association studies to identify genes important in serious adverse drug reactions2012
Dr Tina Biss
Dr Peter Avery
Julian Leathart
Dr John Hanley
Professor Ann Daly
et al.
VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children2011
Professor Ann Daly
Professor Chris Day
A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease2011
Professor Ann Daly
Beyond DME: Genetic determinants of drug-induced liver toxicity2011
Professor Ann Daly
Case Definition and Phenotype Standardization in Drug-Induced Liver Injury2011
Professor Alan Boddy
Professor Ann Daly
Professor Gareth Veal
Characterisation of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases2011
Dr Shyamal Wahie
Professor Ann Daly
Professor Heather Cordell
Dr Andrew Carmichael
Dr Mary Carr
et al.
Clinical and Pharmacogenetic Influences on Response to Hydroxychloroquine in Discoid Lupus Erythematosus: A Retrospective Cohort Study2011
Dr Gul Ozhan
Rajiv Lochan Jayadeva
Julian Leathart
Richard Charnley
Professor Ann Daly
et al.
Cyclooxygenase-2 polymorphisms and pancreatic cancer susceptibility2011
Rajiv Lochan Jayadeva
Professor Ann Daly
Professor Helen Reeves
Richard Charnley
Family history of cancer and tobacco exposure in index cases of pancreatic ductal adenocarcinoma2011
Professor Ann Daly
Dr Stefano Ballestri
Professor Chris Day
Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease2011
Professor Quentin Anstee
Professor Ann Daly
Professor Chris Day
Genetic modifiers of non-alcoholic fatty liver disease progression2011
Professor Quentin Anstee
Professor Ann Daly
Professor Chris Day
Genetics of alcoholic liver disease and nonalcoholic fatty liver disease2011
Professor Ann Daly
Dr Abul Hasnat
Genotypes and phenotypes of CYP3A in Bangladeshi population2011
Julian Leathart
Professor Ann Daly
Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon(R) probes2011
Dr Stefano Ballestri
Professor Chris Day
Professor Ann Daly
Polymorphism in the Farnesyl Diphosphate Farnesyl Transferase 1 Gene and Nonalcoholic Fatty Liver Disease Severity2011
Professor Ann Daly
Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics2011
Professor Chris Day
Dr Peter Donaldson
Professor Ann Daly
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and class II alleles2011
Rajiv Lochan Jayadeva
Professor Ann Daly
Professor Helen Reeves
Richard Charnley
The role of tobacco derived carcinogens in pancreas cancer2011
Julian Leathart
Professor Ann Daly
Professor Chris Day
The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver2011
Elise Andrews
Professor Matthew Wright
Professor Chris Day
Professor Ann Daly
A Role for the Pregnane X Receptor in Flucloxacillin-Induced Liver Injury2010
Professor Ann Daly
Professor Farhad Kamali
A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives2010
Dr Kate Potter
Professor Heather Cordell
Professor Ann Daly
Professor Derek Mann
Professor John Isaacs
et al.
Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFĸB signalling pathways2010
Professor Ann Daly
Drug-induced liver injury: past, present and future2010
Professor Ann Daly
Julian Leathart
Professor Alastair Burt
Professor Chris Day
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease2010
Professor Ann Daly
Genome-wide association studies in pharmacogenomics2010
Ahmad Alserri
Professor Ann Daly
Professor Chris Day
Homozygosity for the Patatin-Like Phospholipase-3/Adiponutrin I148M Polymorphism Influences Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease2010
Dr Peter Donaldson
Professor Ann Daly
Jill Henderson
Professor Chris Day
Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury2010
Dr Fiona Caple
Dr Liz Williams
Dr Alison Spiers
Dr John Tyson
Brian Burtle
et al.
Inter-individual variation in DNA damage and base excision repair in young, healthy non-smokers: effects of dietary supplementation and genotype2010
Professor Ann Daly
Professor Chris Day
Patatin-like phospholipase domain containing 3: A case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease2010
Professor Ann Daly
Pharmacogenetics and human genetic polymorphisms2010
Professor Ann Daly
Polymorphisms in the Tropomyosin TPM1 Short Isoform Promoter Alter Gene Expression and Are Associated With Increased Risk of Metabolic Syndrome2010
Professor Ann Daly
Preempting and preventing drug-induced liver injury2010
Sophie Rowbotham
Professor Alan Boddy
Dr Chris Redfern
Professor Gareth Veal
Professor Ann Daly
et al.
Relevance of non-synonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation2010
Dr Montserrat Briz Del Blanco
Dr Katherine Talks
Dr John Hanley
Dr Patrick Kesteven
Professor Ann Daly
et al.
Reversal of warfarin-induced over-anticoagulation with individualized dosing of oral vitamin K: a pilot study2010
Sophie Rowbotham
Professor Ann Daly
Professor Gareth Veal
Professor Alan Boddy
Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans2010
Professor Ann Daly
Dr Peter Donaldson
Dr Pallav Bhatnagar
Julia Patch
Professor Heather Cordell
et al.
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin2009
Dr Gary Beale
Ahmad Alserri
Dr Luca Miele
Dr Gillian Patman
Professor Ann Daly
et al.
Claudin 10 (CLDN10) - a Candidate Suceptibility Gene for NAFLD Progression2009
Professor Ann Daly
Conference scene: Initiatives of future biobanking in pharmacogenomics2009
Professor Farhad Kamali
Professor Ann Daly
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data2009
Professor Farhad Kamali
Professor Ann Daly
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study2009
Professor Ann Daly
Professor Chris Day
Genetic Association Studies in Drug-Induced Liver Injury2009
Professor Farhad Kamali
Professor Ann Daly
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design2009
Dr Katherine Talks
Dr John Hanley
Dr Patrick Kesteven
Dr Peter Avery
Professor Ann Daly
et al.
Individualised oral vitamin K for reversal of warfarin excessive anticoagulation2009
Dr John Tyson
Dr Fiona Caple
Dr Alison Spiers
Brian Burtle
Professor Ann Daly
et al.
Inter-individual variation in nucleotide excision repair in young adults: effects of age, adiposity, micronutrient supplementation and genotype2009
Professor Ann Daly
Nomenclature for alleles of the cytochrome P450 oxidoreductase gene2009
Professor Ann Daly
Pharmacogenomics of anticoagulants: Steps toward personal dosage2009
Ahmad Alserri
Professor Ann Daly
PNPLA3 Genotype: Relationship to Severity of Non-Alcoholic Fatty Liver Disease2009
Dr Stuart Kendrick
Julian Leathart
Elsbeth Henderson
Dr Nimantha De Alwis
Dr Stephen Stewart
et al.
A 'loss-of-function' mutation in TIRAP, the gene encoding the Toll-like receptor adapter molecule MAL protects against fibrosis in NAFLD but not ALD2008
Professor Ann Daly
Ann K Daly talks to Tarryn Greenberg, Commissioning Editor2008
Elise Andrews
Professor Ann Daly
Flucloxacillin-induced liver injury2008
Dr Peter Donaldson
Dr Pallav Bhatnagar
Julia Patch
Jill Henderson
Julian Leathart
et al.
Flucloxacillin-induced liver injury: the extended MHC 57.1 haplotype as a major risk factor2008
Rajiv Lochan Jayadeva
Professor Ann Daly
Professor Helen Reeves
Richard Charnley
Genetic susceptibility in pancreatic ductal adenocarcinoma2008
Dr Pallav Bhatnagar
Professor Chris Day
Professor Ann Daly
Genetic variants of hepatic transporters and susceptibility to drug induced liver injury2008
Professor Ann Daly
Professor Gerard Stansby
Increased Platelet-monocyte Aggregation in Male Claudicants with the PlA1/A2 Polymorphism of Gp IIb/IIIa2008
Professor Ann Daly
Interview2008
Professor Ann Daly
Pharmacogenomics applications in drug Metabolism: From genotyping to drug label-challenges?2008
Elise Andrews
Professor Matthew Wright
Professor Chris Day
Professor Ann Daly
Relevance of PXR to Flucloxacillin-induced Liver Injury2008
Dr Peter Donaldson
Dr Pallav Bhatnagar
Julia Patch
Jill Henderson
Julian Leathart
et al.
Susceptibility to drug induced liver injury determined by HLA class II genotype2008
Vasileios Pagmantidis
Dr Robert Shiel
Professor John Mathers
Professor Ann Daly
Professor John Hesketh
et al.
Evidence that a polymorphism within the 3'UTR of glutathione peroxidase 4 is functional and is associated with susceptibility to colorectal cancer2007
Dr Ruben Thanacoody
Professor Ann Daly
Dr Joseph Reilly
Emeritus Professor Nicol Ferrier
Professor Simon Thomas
et al.
Factors affecting drug concentrations and QT interval during thioridazine therapy2007
Dr Nimantha De Alwis
Professor Ann Daly
Julian Leathart
Dr Sushma Saksena
Professor Chris Day
et al.
Genetic evidence that lipid trafficking plays a key role in fibrosis in non alcoholic fatty liver disease2007
Professor Ann Daly
Julian Leathart
Richard Swainsbury
Professor Chris Day
Genetic Susceptibility to Diclofenac-Induced Hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 Genotypes2007
Professor Ann Daly
Individualized drug therapy2007
Professor Ann Daly
Pharmacogenetics and pharmacogenomics2007
Professor Ann Daly
Pharmacogenetics of oral anticoagulants2007
Dr Ellen Hatch
Elizabeth Sconce
Dr Barry King
Dr Hilary Wynne
Professor Ann Daly
et al.
Polymorphisms in genes associated with the vitamin K epoxide reductase complex do not affect warfarin dose requirement2007
Professor Ann Daly
Ahmad Alserri
Julian Leathart
Julia Patch
Professor Chris Day
et al.
The mitochondrial superoxide dismutase 2 (SOD2) targeting sequence polymorphism is associated with fibrotic NAFLD: Consistent evidence from case-control and intra-familial allelic association studies2007
Dr Elaine Mutch
Professor Ann Daly
Professor Faith Williams
The Relationship between PON1 Phenotype and PON1-192 Genotype in Detoxification of Three Oxons by Human Liver2007
Dr Ellen Hatch
Elizabeth Sconce
Professor Ann Daly
Professor Farhad Kamali
A rapid genotyping method for the vitamin K epoxide reductase complex subunit 1 (VKORC1) gene2006
Elizabeth Sconce
Professor Ann Daly
Dr Tayyaba Khan
Dr Hilary Wynne
Professor Farhad Kamali
et al.
APOE genotype makes a small contribution to warfarin dose requirements2006
Elizabeth Sconce
Dr Tayyaba Khan
Professor Ann Daly
Dr Hilary Wynne
Professor Farhad Kamali
et al.
Apolipoprotein E polymorphisms do not make a clinically significant contribution to warfarin dose requirements2006
Professor Ann Daly
Association study of the BDNF Val66Met polymorphism with tardive dyskinesia2006
Professor Ann Daly
Dr Barry King
Contribution of CYP2C9 to variability in vitamin K antagonist metabolism2006
Dr Ruben Thanacoody
Professor Ann Daly
Dr Joseph Reilly
Emeritus Professor Nicol Ferrier
Professor Simon Thomas
et al.
Effects of CYP2D6 genotype on QTc interval in recipients of thioridazine2006
Professor Chris Day
Julian Leathart
Professor Ann Daly
Genetic evidence for a role for gut flora in the pathogenesis of NASH in humans2006
Dr Ruben Thanacoody
Professor Ann Daly
Dr Joseph Reilly
Emeritus Professor Nicol Ferrier
Professor Simon Thomas
et al.
Genetic factors influencing steady-state plasma concentrations of thioridazine and its metabolites2006
Professor Ann Daly
Dr Barry King
Julian Leathart
Genotyping for cytochrome P450 polymorphisms2006
Professor Ann Daly
Significance of the minor cytochrome P450 3A isoforms2006
Elizabeth Sconce
Dr Tayyaba Khan
Professor Ann Daly
Dr Hilary Wynne
Professor Farhad Kamali
et al.
Simvastatin results in a lower warfarin dose requirement due to a reduced clearance of warfarin2006
Elizabeth Sconce
Dr Tayyaba Khan
Professor Ann Daly
Dr Hilary Wynne
Professor Farhad Kamali
et al.
The impact of simvastatin on warfarin disposition and dose requirements2006
Dr Barry King
Dr Tayyaba Khan
Professor Farhad Kamali
Professor Ann Daly
[abstract] CYP2C9 polymorphisms and haplotypes: correlation with warfarin dose and metabolism2005
Elizabeth Sconce
Dr Tayyaba Khan
Dr Hilary Wynne
Dr Patrick Kesteven
Dr Peter Avery
et al.
[abstract] Pfizer poster communication prize - The influence of patient age, CYP2C9 genotype and height on warfarin dose requirements2005
Dr Ruben Thanacoody
Professor Ann Daly
Dr Joseph Reilly
Emeritus Professor Nicol Ferrier
Professor Simon Thomas
et al.
Factors affecting steady-state plasma concentrations of thioridazine and its metabolites and electrocardiographic parameters of cardiac repolarisation in patients on chronic thioridazine therapy2005
Emerita Professor Suzanne Cholerton
Professor Ann Daly
Genetic polymorphism of manganese superoxide dismutase (MnSOD) and breast cancer susceptibility2005
Dr Catherine Todhunter
Dr Alison Sutherland
Dr Peter Donaldson
Professor Ann Daly
Emeritus Professor Roger Francis
et al.
Influence of IL-6, COL1A1, and VDR gene polymorphisms on bone mineral density in Crohn's disease2005
Julian Leathart
Professor Ann Daly
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics2005
Ela Kadioglu
Professor Ann Daly
Ser326cys polymorphism in hOGG1 gene and its susceptibility to Barrett's esophagus and esophageal carcinoma2005
Elizabeth Sconce
Dr Tayyaba Khan
Dr Hilary Wynne
Dr Peter Avery
Dr Barry King
et al.
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen2005
Professor Ann Daly
[abstract] Contribution of polymorphisms in xenobiotic metabolism and DNA repair genes to DNA damage and cancer2004
Vanessa Gage
Professor Peter Blain
Julian Leathart
Professor Ann Daly
Professor Faith Williams
et al.
Association of DNA damage to human peripheral lymphocytes with age and MnSOD and OGG1 genotype2004
Professor Ann Daly
Association of metabolic gene polymorphisms with tobacco consumption in healthy controls2004
Professor Farhad Kamali
Dr Tayyaba Khan
Dr Barry King
Dr Patrick Kesteven
Peter Wood
et al.
Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin2004
Professor Ann Daly
CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation2004
Professor Ann Daly
Dr Barry King
CYP3A5 phenotype-genotype correlations in a British population - Response2004
Professor Ann Daly
Development of analytical technology in pharmacogenetic research2004
Professor Chris Day
Professor Ann Daly
Genetic susceptibility to alcoholic liver disease2004
Professor Ann Daly
Dr Barry King
Genotyping of the A6986G polymorphism of CYP3A52004
Professor Ann Daly
Julian Leathart
Professor Chris Day
Hepatic Adducts, Circulating Antibodies, and Cytokine Polymorphisms in Patients with Diclofenac Hepatotoxicity2004
Emerita Professor Suzanne Cholerton
Professor Ann Daly
N-Acetyltransferase (NAT2) Polymorphism and Breast Cancer Susceptibility: A Lack of Association in a Case-Control Study of Turkish Population2004
Professor Ann Daly
Pharmacogenetics of the cytochromes P4502004
Professor Ann Daly
Dr George Rylance
Protein substitutes for PKU: What's new?2004
Emma Davis
Vanessa Gage
Professor Ann Daly
Professor Faith Williams
The contribution of genotype to DNA damage in lymphocytes from healthy volunteers2004
Professor Farhad Kamali
Dr Tayyaba Khan
Dr Barry King
Professor Ann Daly
Dr Hilary Wynne
et al.
The impact of patient age and genetic polymorphism of CYP2C9 on warfarin dose requirements2004
Dr Barry King
Dr Tayyaba Khan
Professor Farhad Kamali
Professor Ann Daly
Upstream and coding region CYP2C9 polymorphisms: Correlation with warfarin dose and metabolism2004
Professor Ann Daly
Dr Santosh Gupta
Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication2004
Professor Ann Daly
Julian Leathart
Professor Chris Day
A "loss-of-function" polymorphism in ICAM-1 protects heavy drinkers from alcoholic liver disease2003
Dr Stuart Dunn
Professor Ann Daly
Dr Trevor Thomas
Altered tropomyosin expression in essential hypertension2003
Professor Ann Daly
Candidate gene case-control studies2003
Dr Barry King
Julian Leathart
Dr Elaine Mutch
Professor Faith Williams
Professor Ann Daly
et al.
CYP3A5 phenotype-genotype correlations in a British population2003
Professor Ann Daly
Cytochrome P450 polymorphisms and the individualization of drug treatment2003
Dr Elaine Mutch
Professor Ann Daly
Julian Leathart
Professor Peter Blain
Professor Faith Williams
et al.
Do multiple cytochrome P450 isoforms contribute to parathion metabolism in man?2003
Professor Ann Daly
Julian Leathart
Dr Beate Haugk
Professor David Jones
Professor Alastair Burt
et al.
Evidence that alcoholic liver disease is due to immune mechanisms in genetically susceptible drinkers2003
Dr Stephen Stewart
Professor Ann Daly
Professor David Jones
Julian Leathart
Professor Chris Day
et al.
Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease2003
Dr Sushma Saksena
Julian Leathart
Professor Alastair Burt
Emeritus Professor Oliver James
Professor Ann Daly
et al.
Genetic evidence supporting the two-hit model of NASH pathogenesis2003
Professor Ann Daly
Genetic Regulation of Warfarin Metabolism and Response2003
Professor Ann Daly
Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients2003
Dr Ruben Thanacoody
Professor Ann Daly
Professor Simon Thomas
Influence of CYP2D6 and CYP2C19 genotypes on the QTc intervals of psychiatric patients taking thioridazine2003
Dr Ruben Thanacoody
Professor Ann Daly
Professor Simon Thomas
Influence of CYP2D6 genotype on the QTc interval and plasma concentration of thioridazine and its metabolites of psychiatric patients taking chronic therapy.2003
Dr Sushma Saksena
Julian Leathart
Professor Ann Daly
Professor Chris Day
Manganese dependent superoxide dismutase (SOD2) targeting sequence polymorphism is associated with advanced fibrosis in patients with non-alcoholic fatty liver disease2003
Dr Barry King
Dr Tayyaba Khan
Professor Farhad Kamali
Professor Ann Daly
Novel CYP2C9 polymorphisms and their relationship to warfarin dose requirements2003
Alison Sutherland-Craggs
Dr John Mansfield
Dr Peter Donaldson
Professor Ann Daly
Dr Nicholas Thompson
et al.
Osteoporosis in Crohn's disease is not determined by vitamin D receptor and interleukin-6 genotype2003
Professor Ann Daly
Dr Barry King
Pharmacogenetics of oral anticoagulants2003
Professor Ann Daly
Pharmacogenetics of the major polymorphic metabolizing enzymes2003
Julian Leathart
Professor Ann Daly
Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide2003
Julian Leathart
Professor Chris Day
Professor Ann Daly
Relationship of UGT2B7 genotype with diclofenac hepatotoxicity2003
Dr Elaine Mutch
Dr Lindsey Ferrie
Christopher Pedder
Professor Faith Williams
Professor Ann Daly
et al.
The role of metabolism in determining the genotoxicity of organophosphate pesticides2003
Professor Farhad Kamali
Professor Ann Daly
Dr Hilary Wynne
Warfarin sensitivity: Be aware of genetic influence2003
Julian Leathart
Professor Chris Day
Professor Ann Daly
Association of udp-glucuronosyltransferase (UGT) 2B7 genotype with diclofenac-induced hepatotoxicity2002
Professor Ann Daly
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations2002
Dr Namrata Bahadur
Julian Leathart
Dr Elaine Mutch
Dr Stuart Dunn
Professor Faith Williams
et al.
CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes2002
Professor Ann Daly
Professor Chris Day
CYP2C9 polymorphism and warfarin dose requirements2002
Professor Ann Daly
CYP2D6 deficiency, a factor in ecstasy related deaths?2002
Emerita Professor Suzanne Cholerton
Professor Ann Daly
Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population2002
Professor Ann Daly
Julian Leathart
Dr Beate Haugk
Professor David Jones
Professor Alastair Burt
et al.
Evidence that alcoholic liver disease is due to immune mechanisms in genetically susceptible drinkers2002
Professor Chris Day
Dr Sushma Saksena
Julian Leathart
Professor Alastair Burt
Emeritus Professor Oliver James
et al.
Genetic evidence supporting the two-hit model of NASH pathogenesis2002
Professor Chris Day
Julian Leathart
Professor Ann Daly
Genetic evidence that fatty liver is involved in the pathogenesis of advanced alcoholic liver disease2002
Professor Ann Daly
Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk2002
Alison Sutherland-Craggs
Dr John Mansfield
Dr Mark Hudson
Professor Ann Daly
Emeritus Professor Roger Francis
et al.
Osteoporosis in Crohn's disease is not determined by NOD2 genotype [abstract]2002
Professor Ann Daly
Emeritus Professor Nicol Ferrier
Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism2002
Professor Ann Daly
Professor Chris Day
Dr Peter Donaldson
Polymorphisms in immunoregulatory genes: towards individualised immunosupressive therapy?2002
Ragen Pfeiffer
Professor Ann Daly
Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: A HuGE review2002
Dr Stephen Stewart
Julian Leathart
Professor Ann Daly
Professor Chris Day
Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis2002
Dr Stephen Stewart
Professor Ann Daly
Julian Leathart
Professor David Jones
Professor Chris Day
et al.
A polymorphism in CTLA-4 is associated with the presence of anti-CYP2E1 antibody titres in patients with alcoholic liver disease2001
Professor Chris Day
Julian Leathart
Professor Ann Daly
Dr Mark Hudson
Association of a 5'-flanking region polymorphism in the interleukin-4 gene with Crohn’s disease in a British population.2001
Professor Chris Day
Julian Leathart
Professor Ann Daly
Dr Mark Hudson
Association of single nucleotide polymorphisms in the interleukin-4 gene and interleukin-4 receptor gene with Crohn's disease in a British population2001
Professor Ann Daly
Professor Chris Day
Candidate gene case-control association studies: advantages and potential pitfalls2001
Professor Ann Daly
Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: A pooled analysis of genotype-based studies2001
Dr Mark Welfare
Professor Ann Daly
Genotype for CYP1A2 and Ah receptor and risk of colorectal cancer in north east England2001
Professor Ann Daly
Human cytochrome P-450 (CYP) genes: A web page for the nomenclature of alleles2001
Professor Ann Daly
Metabolic gene polymorphism frequencies in control populations2001
Professor Ann Daly
Dr Andrew Hall
Pharmacogenetics of cytotoxic drugs2001
Professor Ann Daly
Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?2001
Dr Kaushik Agarwal
Professor Ann Daly
Julian Leathart
Dr Mark Hudson
Professor Chris Day
et al.
Polymorphisms of immunoregulatory genes: A step towards individually tailored immunosuppression?2001
Emma Davis
Professor Ann Daly
Professor Faith Williams
Quantitation of in vitro DNA damage using the comet assay2001
Dr Andrew Harbottle
Professor Ann Daly
Dr Kathryn Atherton
Professor Frederick Campbell
Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance2001
Dr Alison Sutherland
Professor Chris Day
Dr Mark Welfare
Professor Ann Daly
Dr John Mansfield
et al.
Role of polymorphisms in the interleukin-10 gene in determining disease susceptibility and phenotype in inflamatory bowel disease2001
Professor Ann Daly
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression2001
Professor Chris Day
Professor Ann Daly
The genetic basis for non-alcoholic and alcoholic steatohepatitis.2001
Professor Ann Daly
The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants2001
Professor David Jones
Professor Ann Daly
Emeritus Professor Oliver James
Dr Bijayeswar Vaidya
Professor Simon Pearce
et al.
CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis2000
Professor Gary Ford
Professor Ann Daly
CYP2D6 and CYP2C19 genotypes of patients with terodilin cardiotoxicity identified through the yellow card system2000
Professor Gary Ford
Professor Ann Daly
CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system2000
Professor Ann Daly
Emeritus Professor Nicol Ferrier
Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients2000
Professor Ann Daly
Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles2000
Professor Ann Daly
Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation2000
Professor Ann Daly
Professor Margaret Bassendine
Professor Chris Day
Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease2000
Joanne Smart
Professor Ann Daly
Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles County2000
Sandra Campbell
Dr Steven Laval
Professor Ann Daly
Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis2000
Professor Chris Day
Julian Leathart
Professor Ann Daly
Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis2000
Dr Mark Welfare
Professor Margaret Bassendine
Professor Ann Daly
The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects2000
Joanne Smart
Professor Ann Daly
Variation in induced CYP1A1 levels: Relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms2000
Professor Chris Day
Dr Patrick Kesteven
Professor Ann Daly
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications1999
Dr Kaushik Agarwal
Professor David Jones
Professor Ann Daly
Professor Margaret Bassendine
CTLA-4 gene polymorphism and chronicity in viral hepatitis1999
Dr Kaushik Agarwal
Professor David Jones
Professor Ann Daly
Professor Margaret Bassendine
Dr Mark Hudson
et al.
CTLA-4 gene polymorphism and susceptibility to inflammatory bowel disease (IBD)1999
Emeritus Professor Robert Perry
Professor Ian McKeith
Dr Andrew Fairbairn
Professor Jim Edwardson
Professor Ann Daly
et al.
CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy Bodies or Alzheimer's disease1999
Dr Mark Welfare
Emeritus Professor Murray Aitkin
Professor Margaret Bassendine
Professor Ann Daly
Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: Lack of a polymorphism in CYP1A2 in Caucasians1999
Professor Ann Daly
Genetic epidemiology of environmental toxicity and cancer susceptibility: Human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues1999
Professor Ann Daly
Genetic variation of CYP2A6, smoking, and risk of cancer1999
Professor Ann Daly
Dr Mark Welfare
Genotype for codon 105 polymorphism of GSTP1 does not predict susceptibility to UC1999
Professor Ann Daly
Dr Mark Welfare
GSTP1 is not a susceptibility gene for UC1999
Professor Ann Daly
Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method1999
Professor Margaret Bassendine
Professor Ann Daly
Polymorphisms in GSTP1, GSTM1, and GSTT1 and susceptibility to colorectal cancer1999
Mike Cole
Emerita Professor Suzanne Cholerton
Professor Ann Daly
Professor Andrew Pearson
Professor Alan Boddy
et al.
The effect of fluconazole on cyclophosphamide metabolism in children1999
Professor David Jones
Professor Julia Newton
Professor Ann Daly
Professor Chris Day
Emeritus Professor Oliver James
et al.
Tumour necrosis factor-α promoter polymorphisms in primary biliary cirrhosis1999
Professor Chris Day
Dr Patrick Kesteven
Professor Ann Daly
Warfarin dose requirement and CYP2C9 polymorphisms - Reply1999
Professor Ann Daly
Professor Margaret Bassendine
Emeritus Professor Oliver James
Professor Chris Day
The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: Effect on age of presentation and dependence on alcohol dehydrogenase genotype1998
Professor Ann Daly
Lung cancer risk in relation to the CYP2E1 Rsa I genetic polymorphism among African-Americans and Caucasians in Los Angeles County1996
Professor Alan Boddy
Emerita Professor Suzanne Cholerton
Professor Ann Daly
Professor Andrew Pearson
Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide1994
Professor Alan Boddy
Emerita Professor Suzanne Cholerton
Professor Ann Daly
Professor Janice Ellis
Julian Leathart
et al.
The pharmacogenetics of chemical carcinogenesis1992
Dr Chris Redfern
Professor Ann Daly
Cellular retinoic acid-binding protein from neonatal rat skin: Purification and analysis1990
Professor Ann Daly
Dr Chris Redfern
Identification and analysis of retinoic acid-binding proteins and receptors from nuclei of mammalican cells1990
Dr Chris Redfern
Professor Ann Daly
Carole Todd
The biological activity of retinoids in melanoma cells: Induction of expression of retinoic acid receptor-β by retinoic acid in S91 melanoma cells1990
Professor Jonathan Rees
Professor Ann Daly
Dr Chris Redfern
Differential expression of the alpha and beta retinoic acid receptors in tissues of the rat1989
Professor Ann Daly
Professor Jonathan Rees
Dr Chris Redfern
Nuclear retinoic acid binding proteins and receptors in retinoic acid responsive cell lines1989
Professor Ann Daly
Dr Chris Redfern
Retinoic acid receptor expression in some retinoic acid responsive cell-lines1989
Professor Ann Daly
Dr Chris Redfern
Purification and properties of cellular retinois acid-binding protein from neonatal rat skin1988
Professor Ann Daly
Dr Chris Redfern
Characterisation of a retinoic-acid-binding component from F9 embryonal-carcinoma-cell nuclei1987
Professor Ann Daly
Dr Chris Redfern
The binding of retinoic acid to nuclei and nuclear subfractions1985